Corbus Pharmaceuticals Files 8-K

Ticker: CRBP · Form: 8-K · Filed: Nov 4, 2024 · CIK: 1595097

Sentiment: neutral

Topics: corporate-filing, listing

Related Tickers: CRBP

TL;DR

CRBP filed an 8-K, confirming its Nasdaq listing and corporate details.

AI Summary

Corbus Pharmaceuticals Holdings, Inc. filed an 8-K on November 4, 2024, reporting its corporate information. The company is incorporated in Delaware and its principal executive offices are located at 500 River Ridge Drive, Norwood, Massachusetts. Its common stock trades on The Nasdaq Capital Market under the ticker symbol CRBP.

Why It Matters

This filing provides essential corporate details and confirms the trading status of Corbus Pharmaceuticals' common stock on Nasdaq.

Risk Assessment

Risk Level: low — This is a routine corporate filing with no new material financial or operational information disclosed.

Key Players & Entities

FAQ

What is the company's principal executive office address?

The company's principal executive offices are located at 500 River Ridge Drive, Norwood, Massachusetts, 02062.

On which exchange does Corbus Pharmaceuticals' common stock trade?

Corbus Pharmaceuticals' common stock trades on The Nasdaq Capital Market.

What is the trading symbol for Corbus Pharmaceuticals' common stock?

The trading symbol for Corbus Pharmaceuticals' common stock is CRBP.

In which state is Corbus Pharmaceuticals incorporated?

Corbus Pharmaceuticals is incorporated in Delaware.

What is the date of this 8-K filing?

The date of this 8-K filing is November 04, 2024.

Filing Stats: 825 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-11-04 07:51:09

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 4, 2024, Corbus Pharmaceuticals Holdings, Inc. (the "Company") issued a press release announcing pre-clinical data for CRB-913 that is being presented at Obesity Week 2024. A copy of the press release is attached hereto as Exhibit 99.1. The Company also updated its presentation used by management to describe its business. A copy of the presentation is furnished as Exhibit 99.2 and is incorporated herein by reference. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibits 99.1 and 99.2, is being furnished to the Securities and Exchange Commission (the "SEC"), and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.

01 Other Events

Item 8.01 Other Events. The Company is presenting new pre-clinical data for CRB-913 at Obesity Week 2024. CRB-913 is a second-generation highly peripherally restricted CB1 receptor inverse agonist designed to treat obesity. The Company is currently conducting IND-enabling studies and expects to treat the first patient in a Phase 1 study in the first quarter of 2025. Key findings: CRB-913 brain levels (both C max and AUC) were 15-fold lower than monlunabant at the same dose in mice. Plasma-to-brain ratio for CRB-913 was 10 times higher than monlunabant and 50 times higher than rimonabant at the same dose. CRB-913 demonstrated a wide dose response weight loss curve in diet-induced obesity ("DIO") mice ranging from 5 mg/kg/day to 80 mg/kg/day with no plateauing effect and reaching a weight loss of 31% by day 19. Extending the dosing at 80 mg/kg/day to 28 days resulted in an additional weight loss reaching 38%. Allometrically, this dose range corresponds to human-equivalent doses of 30 mg/day to 450 mg/day. A first-of-its-kind experimental protocol in DIO mice demonstrated that weight loss induced by an incretin analog (semaglutide) can be maintained post withdrawal by replacing it with a CB1 inverse agonist (CRB-913) whereas replacement of semaglutide with vehicle led to a rapid and complete regain of weight. DEXA-scanning data revealed that switching from semaglutide to CRB-913 in DIO mice led to additional weight loss that was driven by a doubling in fat percentage reduction compared to the corresponding semaglutide maintenance cohort. This indicates a peripheral effect on fat metabolism not present with semaglutide.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated November 4, 2024. 99.2 Investor Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Corbus Pharmaceuticals Holdings, Inc. Date: November 4, 2024 By: /s/ Yuval Cohen Name: Yuval Cohen Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing